Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mirtazapine, an antidepressant

T Puzantian1

  • 1San Francisco General Hospital, CA, USA.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|January 23, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ecstasy: dangers and controversies.

Pharmacotherapy·2002
Same author

Psychiatric pharmacists.

The American journal of psychiatry·2001
Same author

Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters.

Therapeutic drug monitoring·1999
Same author

Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants?

Pharmacotherapy·1999
Same author

Nefazodone and symptoms suggesting neurotoxicity: a case report.

The Journal of clinical psychiatry·1996
Same author

Criteria for use of valproate in adult psychiatric inpatients and outpatients.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1996

Mirtazapine is an effective antidepressant that works by blocking specific receptors. Clinical trials show it improves depression scores and is well-tolerated, with potential benefits for anxiety.

Area of Science:

  • Pharmacology and Clinical Therapeutics
  • Neuroscience
  • Psychiatry

Background:

  • Mirtazapine is a novel antidepressant agent.
  • It functions by antagonizing presynaptic alpha 2-adrenergic autoreceptors and heteroreceptors, as well as postsynaptic serotonin 5-HT2 and 5-HT3 receptors.
  • The drug is FDA-approved for treating depression and shows potential for anxiolytic and sedative effects.

Purpose of the Study:

  • To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosing of mirtazapine.
  • To evaluate its effectiveness in treating depression and potential comorbid anxiety disorders.

Main Methods:

  • Review of existing pharmacological data, pharmacokinetic studies, and clinical trial results.
  • Assessment of efficacy using depression rating scales, such as the Hamilton Rating Scale for Depression (HAM-D).

Related Experiment Videos

  • Analysis of reported adverse effects and drug interactions.

    • Main Results:

    • Mirtazapine is rapidly absorbed orally and suitable for once-daily dosing due to hepatic biotransformation.
    • Clinical trials demonstrated significantly greater improvement in depression scores for mirtazapine compared to placebo.
    • Efficacy was comparable to established antidepressants like amitriptyline, clomipramine, and doxepin.

    Conclusions:

    • Mirtazapine is an effective and well-tolerated antidepressant.
    • Common side effects include somnolence, increased appetite, weight gain, and dizziness.
    • The drug shows promise for treating depression, with potential benefits for co-occurring anxiety disorders.